No photo of Sunandana Chandra

View Scopus Profile

Sunandana Chandra

  • 371 Citations
20122022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.

Training Experience

2011Residency, Case Western Reserve University Hospital
2014Fellowship, New York University Medical Center

Education/Academic qualification

MD, Michigan State University

… → 2008

MS, Michigan State University

… → 2003

Keywords

  • Cancer of Unknown Primary
  • Clinical Research
  • Drug Discovery
  • Melanoma
  • Skin Cancer

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Precision Medicine Medicine & Life Sciences
CTLA-4 Antigen Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2022

Prot #2125-MEL-301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Chandra, S.

Medpace Clinical Research LLC, Idera Pharmaceuticals, Inc.

4/9/19 → 4/9/22

Project: Research project

Prot #CA224047: A Randomized Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unrsectable Melanoma

Chandra, S.

Bristol-Myers Squibb Company

3/21/19 → 3/21/22

Project: Research project

Prot #MK3475-716: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

Chandra, S.

DrugDev Inc., Merck Sharp & Dohme Corp.

10/25/18 → 10/25/21

Project: Research project

Prot #UWSC10294/NU UWF17D02: A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti‐PDL‐1 Antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases

Chandra, S.

University of Washington, EMD Serono Research & Development Institute, Inc.

4/1/18 → 5/31/22

Project: Research project

Prot #R2810-ONC-1620: A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of

Alam, M. & Chandra, S.

ICON Clinical Research Limited, Regeneron Pharmaceuticals, Inc.

12/1/17 → 12/1/20

Project: Research project

Research Output 2012 2019

Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

Johnson, D. B., Chandra, S. & Sosman, J. A., Mar 26 2019, In : JAMA - Journal of the American Medical Association. 321, 12, p. 1219-1220 2 p.

Research output: Contribution to journal › Letter

Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A. W., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 othersGibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Research output: Contribution to journal › Article

Colitis
Steroids
Therapeutics
Prednisone
Melanoma

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

Eroglu, Z., Holmen, S. L., Chen, Q., Khushalani, N. I., Amaravadi, R., Thomas, R., Ahmed, K. A., Tawbi, H., Chandra, S., Markowitz, J., Smalley, I., Liu, J. K. C., Chen, Y. A., Najjar, Y. G., Karreth, F. A., Abate-Daga, D., Glitza, I. C., Sosman, J. A., Sondak, V. K., Bosenberg, M. & 7 othersHerlyn, M., Atkins, M. B., Kluger, H., Margolin, K., Forsyth, P. A., Davies, M. A. & Smalley, K. S. M., May 1 2019, In : Pigment Cell and Melanoma Research. 32, 3, p. 458-469 12 p.

Research output: Contribution to journal › Article

Open Access
Neurology
Melanoma
Central Nervous System
Neoplasm Metastasis
Brain
2 Citations (Scopus)

Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma

Cavalcante, L., Chowdhary, A., Sosman, J. A. & Chandra, S., Oct 1 2018, In : American Journal of Clinical Dermatology. 19, 5, p. 657-670 14 p.

Research output: Contribution to journal › Review article

Melanoma
Vaccination
Clinical Trials
CD274 Antigen
Neoplasms
19 Citations (Scopus)

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Chae, Y. K., Arya, A., Iams, W., Cruz, M. R., Chandra, S., Choi, J. & Giles, F., May 16 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 39.

Research output: Contribution to journal › Review article

Non-Small Cell Lung Carcinoma
Immunotherapy
Melanoma
Clinical Trials
CTLA-4 Antigen